Drug Trial Radar · NCT05191563
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.
Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jul 31, 2021
Primary completion
Sep 12, 2021
Study completion Sep 12, 2021
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An Open-Label, Randomized, Single-Dose Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects
Conditions
- Healthy
Interventions
HCP1904-1Drug
Take it once per period.
RLD2006Drug
Take it once per period.
RLD2001-2Drug
Take it once per period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of LosartanTime frame: Day 1, Day 15: pre-dose(0 hour)~48hours
- AUClast of LosartanTime frame: Day 1, Day 15: pre-dose(0 hour)~48hours
- Cmax of EXP3174Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
- AUClast of EXP3174Time frame: Day 1, Day 15: pre-dose(0 hour)~48hours
- Cmax of ChlorthalidoneTime frame: Day 1, Day 15: pre-dose(0 hour)~144hours
- AUClast of ChlorthalidoneTime frame: Day 1, Day 15:pre-dose(0 hour)~144hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yangji Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.